Relmada Therapeutics, Inc. (RLMD), Tuesday announced that the company has secured an exclusive licensing for NDV-01 with Trigone Pharma, Ltd. for the treatment of Non-Muscle Invasive Bladder Cancer.
NDV-01 is currently being evaluated in a Phase 2, single-arm study to assess safety and efficacy. The topline data from the first 20 patients in the study are expected to be presented in April.
The company stated that it continues to evaluate additional strategic product opportunities to leverage the extensive development capability that it has built over the past several years.
In the pre-market hours, Relmada's stock is trading at $0.31, up 3.37 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.